Drug Trial Radar · NCT06682000
Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension
Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
192
Actual
Start
Jan 20, 2025
Primary completion
Oct 2, 2025
Study completion Oct 2, 2025
Sponsor
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.Industry
- Sponsor type
- Industry
- First posted
- Nov 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of DWC202404 and DWC202314 Combination Therapy in Patients with Essential Hypertension Inadequately Controlled on DWC202404 Monotherapy
Conditions
- Hypertension
- Essential Hypertension
Interventions
DWC202404, DWC202314Drug
\- 2 tablet, Oral, Once a day
DWC202404, DWC202314PDrug
\- 2 tablet, Oral, Once a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of MSSBP (Mean Sitting Systolic Blood Pressure) based on baselineTime frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hanyang University Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.